There are ongoing trials evaluating durvalumab in combination with other drugs, including tremelimumab (a fully human monoclonal antibody against CTLA-4) [NCT01975831] [102] and MEDI0680 (AMP-514) (a humanized IgG4 monoclonal antibody against PD-1) [NCT02118337] [103] for patients with advanced malignancies including RCC. The gene discussed is PDCD1; the disease is renal cell carcinoma.